Sildenafil Citrate Tablet
Product Images NDC 70954-407

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 70954-407). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label1 (Container1)

Label for Sildenafil Tablets USP 25 mg by Novitium Pharma LLC. The label states each tablet contains sildenafil citrate equivalent to 25 mg sildenafil, with a 30-tablet count. It includes storage instructions, dispensing guidelines, and a barcode. The label shows the NDC 70954-407-10 and the issued date 07/2022.*

FDA Label Image

Label2 (Container2)

Sildenafil Tablets USP 50 mg oral tablets packaging label showing quantity of 30 tablets. The label includes storage instructions, dosage note, Rx only indication, bar code, manufacturer Novitium Pharma LLC in New Jersey, and spaces for lot number and expiry date. The brand name and strength are prominently displayed.*

FDA Label Image

Label3 (Container3)

Label for Sildenafil Tablets, USP 100 mg by Novitium Pharma shows a 30-tablet bottle with storage and dispensing instructions, barcode, manufacturing details, and Rx only notation. The label specifies each tablet contains sildenafil citrate equivalent to 100 mg sildenafil.*

FDA Label Image

Figure2 (Figure 2)

A line graph comparing the change in EF (mL/CG) over time in hours postdose between two treatments: Doxazosin plus placebo and Doxazosin plus Sildenafil 25 mg. The graph shows time on the x-axis (0 to 8 hours) and change in EF on the y-axis, illustrating the effects of the treatments over the 8-hour period.*

FDA Label Image

Figure-3 (Figure 3)

A line graph showing the change in systolic blood pressure (SBP) over time postdose in hours. It compares two treatments: Doxazosin + Placebo (blue line with circle markers) and Doxazosin + Sildenafil 50 mg (black line with diamond markers), illustrating the blood pressure trends over an 8-hour period.*

FDA Label Image

Figure-4 (Figure 4)

A line graph showing changes in mmHg pressure over time after dosing, comparing the effects of Doxazosin plus Sildenafil 100 mg versus Doxazosin plus Placebo. The x-axis represents time after dosing in hours, and the y-axis represents pressure in mmHg, ranging from -50 to 40.*

FDA Label Image

Figure-7 (Figure 7)

A bar graph showing the percentage of patients reporting improvement across different treatment groups. The x-axis lists Placebo, Sildenafil 25 mg, Sildenafil 50 mg, and Sildenafil 100 mg groups, while the y-axis indicates the percentage reporting improvement from 0 to 100%. The percentages for each group are 24% for placebo, 63% for Sildenafil 25 mg, 74% for Sildenafil 50 mg, and 82% for Sildenafil 100 mg.*

FDA Label Image

Figure1 (Figure1)

A line graph comparing systolic blood pressure (mmHg) over time post-dose (hours) between Sildenafil 100 mg and placebo. The x-axis represents time up to 24 hours, and the y-axis shows changes in systolic blood pressure. Sildenafil and placebo groups are plotted with distinct markers and lines.*

FDA Label Image

Figure5 (Figure5)

Chart showing mean plasma concentrations of Sildenafil over 24 hours in healthy male volunteers following administration of a commercial tablet. The graph plots plasma concentration (ng/mL) on the vertical axis against time post-dose (hours) on the horizontal axis, illustrating the drug's pharmacokinetic profile after oral dosing.*

FDA Label Image

Figuree (Figuree)

Two bar graphs illustrating the effect of Sildenafil and placebo on maintenance of erection by baseline score. The y-axis shows percentage of patients at endpoint, and the x-axis shows baseline scores from 0 to 5. Different bars represent score categories 0 to 5, comparing Sildenafil and placebo outcomes.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Sildenafil Citrate showing the molecular arrangement of atoms including carbon, nitrogen, oxygen, and sulfur in its molecular framework.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.